Z-Alpha pulls in $7.48M round as global pharma joins alpha-therapy bet
What's the deal? Z-Alpha, a US biotech developing targeted alpha radiopharmaceuticals, raised US$8.38M in a late-stage venture round. Korea's d&d pharmatech led the investment alongside existing backers OrbiMed and Tybourne Capital, with an unnamed global pharmaceutical company joining as a new strategic investor.
What's the endgame? Z-Alpha builds cancer therapies using astatine-211, a radioactive isotope that delivers alpha particles directly to tumours. The approach aims to attack cancer cells while limiting damage to nearby healthy tissue, and the company will use the funds to advance multiple candidates toward clinical trials in 2027.
Why now? d&d pharmatech first partnered with Z-Alpha in 2022, contributing alpha-therapy assets from its US subsidiary Neuraly to form a joint venture. It is now the third-largest shareholder, and chief executive officer Seulki Lee sits on Z-Alpha's board.
This round marks a shift: d&d pharmatech invested directly rather than through its US subsidiary. "This investment is one the company participated in directly to raise the expected returns," Lee said (translated from Korean).
What could go wrong? Astatine-211 has a half-life of roughly 7.2 hours. That short window makes securing production facilities and a fast supply chain a key hurdle to commercialisation. The participating pharma company's name and investment size were not disclosed, and Z-Alpha's candidates remain early-stage, targeting their first clinical entry in 2027.
The signal: Targeted alpha radiotherapy has drawn large capital this year. AdvanCell raised $315 million in July to push lead-212 therapies into late-stage development, and Aktis Oncology expanded funding in November with investors including a Merck-affiliated backer. Those peers hold clinical-stage assets and manufacturing bases, so Z-Alpha's small round signals interest in the field rather than proof of commercial success.
Read more: edaily.co.kr
Image credit: UrologySanAntonio
